잠시만 기다려 주세요. 로딩중입니다.

COVID-19 치료제

Obstructive Lung Disease 2021년 9권 1호 p.11 ~ 15
이예진, 박용범,
소속 상세정보
이예진 ( Lee Ye-Jin ) - Hallym University Kangdong Sacred Heart Hospital Department of Internal Medicine
박용범 ( Park Yong-Bum ) - Hallym University Kangdong Sacred Heart Hospital Department of Internal Medicine

Abstract


A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), was first identified in December 2019 Wuhan, China. Today, COVID 19 has officially become a pandemic and the number of newly confirmed COVID 19 patients has exceeded 1,000 every day, the highest ever in Korea. Many randomized control trials have been evaluated for the treatment of COVID 19, only dexamethasone and remdesivir have proven effective in severe COVID 19 patients who require oxygen supplementation, whereas, hydroxychloroquine was failed to show efficacy. In addition, several antibodies from convalescent plasma for COVID 19 is still under clinical trial and is not approved. Currently, considerable efforts have been put into developing effective and safe vaccines against SARS-COV-2. Global pharmaceutics e.g, Astrazeneca, Moderna, and Pfizer are developing RNA or non-replicating vector vaccines and we hope that these vaccines provide acquired immunity against COVID-19 with safety.

키워드

SARS-COV-2; COVID-19; Hydroxychloroquine; Dexamethasone; Remdesivir; Antibodies; Vaccine against COVID-19

원문 및 링크아웃 정보

등재저널 정보